In the last three decades, ischemic heart disease, stroke, and diabetes became leading causes of mortality and years of life lost (YLL), although with some divergences among countries in the ratio of observed and expected YLLs which is based on sociodemographic indexes.
disease at baseline, a rise in BP levels is associated strongly with the age-specific mortality rates from CV events. 5 A 20 mm Hg difference in usual SBP is approximately equivalent in its hazards to a 10 mm Hg difference in usual diastolic blood pressure (DBP). In particular, an elevation of 20 mm Hg accounts for many increases in strokes, coronary syndromes, and mortality. 6 These relationships between BP levels and vascular mortality show a remarkable, continuous association starting from SBP of 115 mm Hg and DBP of 75 mm Hg for each decade of age. 5 
| THE IMP ORTAN CE OF REDUCING B LOOD PRE SSURE TO PRE VENT C ARDIOVA SCUL AR OUTCOME S
The benefits of hypertension treatments aimed to lower BP for prevention of CVD are well established. A 10 mm Hg decrease in SBP reduces the risk of major CVD events by 20%, coronary heart disease by 17%, stroke by 27%, heart failure by 28%, and all-cause mortality by 13%, 7 while a decrease in DBP has been linearly related to a lower risk of recurrent stroke (P = 0.026) and all-cause mortality (P = 0.009). 8 Reduction of CV risk is proportional to the decrease of SBP, DBP, and pulse pressure (PP), but the logarithmic nature of this relationship implies that risk reduction increases to a progressively smaller extent the larger the BP reduction. 9 The effects of BP lowering are broadly similar even in the presence of concomitant comorbidities or previous CVD, coronary heart disease, or cerebrovascular disease. 7 Indeed, the extent of both SBP and DBP decrease is directly associated with the magnitude of risk reduction in recurrent cerebrovascular and CV events. These findings highlight the importance of a strict and aggressive BP control, which is increasingly being considered as the most essential therapeutic strategy for an effective CVD prevention, particularly in case of pre-existing CVD. For instance, achieving a SBP <130 mm Hg seems to be invaluable for secondary stroke prevention in patients with cerebrovascular events. 8 Controlling and lowering BP is per se functional to reduce CV risk, independently of the antihypertensive approaches used ( Figure 1 ) and produces a significant improvement in outcome in all hypertension grades. 10 For instance, in the presence of grade 1 hypertension at low-to-moderate risk, lowering BP induces a reduction in stroke (risk ratio, RR = 0.33), coronary events (RR = 0.68),
and death (RR = 0.53); the SBP cut-off values are across 150 and 140 mm Hg; below 130 mm Hg only stroke and all-cause death are significantly reduced. 9 Furthermore, after stratifying patients per increasing 10-year incidence of CV death, the relative reduction in all outcomes by BP lowering does not differ among strata and the absolute risk decreases in very high-risk patients. 11 In patients at high risk for the presence of diabetes mellitus, BP reductions in 5-10 mm Hg significantly contribute to reduce the relative risk of coronary heart disease, heart failure, and all-cause death; these results are amplified in hypertensive patients with diabetes who show a significantly greater relative risk reduction of coronary heart disease and all-cause death, obtained by a more intensive BP control. 12 In general, when an intensive BP lowering is achieved, the risk ratio of stroke (RR = 0.71), coronary events (RR = 0.80), major CV events (RR = 0.75), and CV mortality (RR = 0.79) further improve; heart failure and all-cause death do not change. 13 Even in patients in the high normal range with an estimated risk higher than 10%, an intensive antihypertensive strategy aimed at reach- Treatments aimed to lower BP may be important to reduce CVD risk even in individuals with normal or high normal blood pressure, but risk reduction is limited to stroke. 15 
| THE PL ACE OF ANG I OTEN S IN RECEP TOR B LO CK ER S IN THE TRE ATMENT OF HYPERTEN S I ON AND A SSO CIATED C ARDIOVA SCUL AR CONDITIONS
Systematic reviews have shown that BP lowering by all classes of antihypertensive drugs is matched with significant reductions in stroke and major CV events. Although some minor differences among classes have been observed for prevention of specific outcomes (eg, overall mortality), there is a general homogeneity in the observed benefits ( Figure 2) . 10 This supports the concept that reduction in these events is highly related to the BP-lowering properties beside potential-specific drug properties. Accounting for equivalent antihypertensive properties, the effects of drug classes on overall CV risk are similar, but some difference can be noticed in reducing specific risks: diuretics result as superior in preventing heart failure; beta-blockers are less effective in protecting from stroke; calcium antagonists are superior in preventing stroke and all-cause death, but inferior in preventing coronary heart disease; ARBs are more effective in preventing heart failure. 18 Indeed, ARBs are associated with a significant relative reduction in heart failure (−10%), stroke (−9%), and major CV events-composite of stroke, coronary heart disease, heart failure-(−9%), although they produce a rather small difference in SBP/DBP compared to placebo (about −3.7/−2.0 mm Hg), which may be due to the fact that in comparative studies patients in the placebo groups were often treated with active CV drugs. ARBs have additional properties which make them particularly effective in reducing proteinuria and improving outcomes in chronic heart failure. These properties are especially important to treat patients with nephropathy, since the relationship between BP and progression of CKD and incident endstage renal disease is direct and progressive. Several randomized trials have clearly demonstrated that RAS blockade is more effective in reducing albuminuria than either placebo or other antihypertensive agents in diabetic nephropathy, nondiabetic nephropathy, and in patients with CVD and is also effective in preventing incident microalbuminuria. 19, 20 Hypertension is a leading cause for heart failure,
and BP lowering has been described as an invaluable strategy to prevent this complication in all patients, including in very elderly patients. 23 Correcting cardiac overstimulation by sympathetic system and the RAS, rather than exclusively lowering BP is the mechanism by which these agents contribute to reduce the risk of heart failure.
Angiotensin blockade is a major therapeutic strategy in patients with 
| ARE ANG I OTEN S IN RECEP TOR B LO CKER S ALL EQUAL S? THE ROLE OF OLME SARTAN
Angiotensin receptor blockers have a well-recognized antihypertensive activity, and although they share many common features, some pharmacokinetic and pharmacodynamic differences have been found among the components of this group (Table 1) .
The head-to head comparison among ARBs is quite controversial, since each published study shows some confounding factors and study designs are often heterogeneous. However, two recent meta-analyses try to summarize the results of randomized trials and provide an overview on the effect of ARBs in BP lowering, highlighting the differences among the components of this class. In this review, we focus our attention on results concerning olmesartan.
In a meta-analysis on 22 studies (4892 subjects), Wang et al ACE, Angiotensin-Converting Enzyme; ARB, Angiotensin II Receptor Blocker; CV, Cardiovascular; NYHA, New York Heart Association.
| OLME SARTAN AND 24 -HOUR B LOOD PRE SSURE CONTROL
Considering the slight differences in their pharmacokinetic and pharmacodynamic, the choice of specific ARBs may affect the entity and the timing of BP reduction and the dose may be particularly important.
Although specific drug or dose usually does not affect the reduction in office and awake SBP, they may influence the effects on SBP over the 24 hours, at night, and during the last 4 hours. Furthermore, variation in dosing may enhance the possibility of prolonging BP reduction during the nocturnal period. Concerning DBP, the type of ARB is determinant to modify BP reduction in the office, during the 24 hours, in the awake and sleep periods; the dosage is even important for differential nocturnal DBP reduction. 47 Compared to other ARBs, olmesartan shows efficacy in reducing 24-hour SBP (P = 0.03) and DBP (P = 0.002), awake (P = 0.008) and DBP (P = 0.002), and SBP (P = 0.02) and DBP (P = 0.04) during the last 4 hours of the dosing interval (Figure 4) . 47 Therefore, olmesartan provides additional advantages in controlling BP as compared to other ARBs, since it allows a larger BP reduction over the 24 hours. with losartan, valsartan, and irbesartan. 49 Therefore, olmesartan provides a favorable action in lowering and, especially, controlling BP and this aspect is particularly important for reducing CV risk. risk. An initial increase in BPV within 24 hours is an independent predictor of progression of subclinical organ damage, CV events, and CV mortality. 50, 51 Similarly, long-term day-by-day BPV is associated with a higher prevalence and severity of cardiac, vascular, and renal organ damage and with an increased risk of fatal and nonfatal CV events. 51 The impact on 24-hour BP control, BPV, and 24-hour distribution of BP reduction has been recently determined for olmesartan alone or in combination with one or two other antihypertensive drugs in a large pooled individual data analysis of ten randomized controlled studies. 52 Active treatment with olmesartan or comparators, but not placebo, reduced SBP and DBP during the whole 24 hours, and the reduction was well maintained during the day and during the night, with larger effects during the waking hours ( Figure 5 ). Interestingly the mean BP reduction was significantly larger after combination treatment than with monotherapies and increased with the intensity of the combination. Placebo had no effect on BPV, small effects were observed under monotherapies, whereas the greatest effect was reported in the combination F I G U R E 5 Adjusted 24 hour, day and night systolic (SBP) and diastolic blood pressure (DBP) mean changes (95% confidence interval) from baseline after double blind treatment with placebo (n = 119), active control monotherapy (n = 1195), olmesartan monotherapy (n = 1410), active control dual combination therapy (n = 79), olmesartan dual combination therapy (n = 637), and olmesartan triple combination therapy (n = 102). The statistical significance of differences between individual pairs of treatments is indicated by the P-value. Changes are adjusted for baseline value, age, sex, body mass index, and region [Redrawn from 52 with permission] groups, when olmesartan was combined with dihydropyridine calcium-channel blockers or thiazide diuretic or was present in a triple combination therapy. 52, 53 Treatment with olmesartan monotherapy resulted in smoothness indexes significantly larger than with active control, and dual and triple combinations achieved smoothness indexes significantly larger than under corresponding monotherapies; the treatment on variability index (TOVI) showed the same trend of smoothness index ( Figure 6 ). Therefore, olmesartan administered in combination with one or two other antihypertensive drugs, allowed a superior 24-hour BP control than placebo or monotherapies (even including olmesartan). 52 The achievement of a more homogeneous and sustained BP control, with reduced BPV, may represent a desirable feature of a given antihypertensive drug treatment, because it may help in preventing the CV consequence associated with uncontrolled arterial hypertension.
52,54,55
| SAFE T Y OF ANG I OTEN S IN RECEP TOR BLOCKER S
All classes of antihypertensive drugs, although able to significantly reduce the risk of major CV events, significantly increase the risk of adverse events leading to permanent treatment discontinuations, with the distinct exception of ARBs which differ from all other classes for the lowest risk of discontinuation. As shown in Figure 7 , the risk of discontinuation for an adverse event was reduced by 29% with ARB treatment, by 10% with diuretics, and by 2% with calcium-channel blockers, whereas it was increased by 18% with ACE-inhibitors and by 13% with beta-blockers. 56 Since ARBs act on renin-angiotensin system to produce the angiotensin II that is not only an effective hypertensive agent, but it also regulates cell growth, their potential for an increased risk of cancer has been widely investigated. Except a meta-analysis that in 2010 described a relationship between cancer and ARBs, no evidence supports that the use of ARBs raises the risk of tumor development. 57 In this regard, a critical commentary took into consideration the mechanisms underlying the potential link between
ARBs and cancer and concluded that, if anything, ARBs are likely to be involved with a prevention of cancer, rather than a promotion. The tolerability profiles of ARBs are similar to placebo and superior to ACE inhibitors. For example, ACE inhibitors increase the risk of cough two-to threefold over placebo and may cause up to 0.1%-0.2% rates of angioedema, while with ARBs, the risk of cough was comparable to placebo (RR = 1.01, 95% CI: 0.74-1.39). 56 However, compared to placebo, ARBs were associated with higher risk of renal dysfunction, hypotension, and hyperkalemia; despite these findings, discontinuation events in patients treated with ARBs, diuretics, or placebo were similar.
62
Olmesartan shows similar tolerability in terms of incidence of adverse events, as other ARBs (losartan, valsartan, candesartan, and irbesartan), with similar relative risk of dizziness, headache, and diarrhea as losartan or valsartan and it is well tolerated even in combination with diuretics or amlodipine. 41 In 2012, a case series of sprue-like syndrome at the Mayo Clinic which was linked to the use of olmesartan was reported. This syndrome is characterized by severe diarrhea and spruelike histopathologic findings in the intestine, often with increased subepithelial collagen. 59 Some clinicopathological findings were described in patients taking ARBs other than olmesartan; therefore, the sprue-like enteropathy, which has indeed a low incidence, seems to be a class effect, rather than an olmesartan-related adverse event.
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| CON CLUS IONS
Lowering and controlling BP are important strategies to decrease the risk of CV events and CV mortality in both hypertensive and 
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F I G U R E 7
Comparisons of the effects of blood pressure-lowering treatments based on diuretics, beta-blockers, calcium antagonists, and angiotensin-converting enzyme inhibitors vs all other classes of drugs excluding angiotensin receptor blockers. The type of cardiovascular events considered was the composite of stroke and coronary heart disease or the composite of stroke, coronary heart disease, and heart failure, as indicated. ACEI, angiotensin-converting enzyme inhibitors; All, all other classes together; ARB, angiotensin receptor blockers; BB, beta-blockers; CA, calcium antagonists; CHD, coronary heart disease; CI, confidence interval; D, diuretics; HF, heart failure; RR, risk ratio 
